Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.42 -3.7%	$5.74	$4.35 ▼ $12.38	$322.73M	0.42	209,409 shs	152,493 shs
BMY Bristol-Myers Squibb	$49.71 -1.9%	$48.78	$39.35 ▼ $63.33	$101.15B	0.38	13.02 million shs	9.17 million shs
GPH Graphite One	C$0.77 -2.5%	C$0.86	C$0.55 ▼ C$1.07	C$77.97M	1.02	70,365 shs	80,563 shs
OGN Organon & Co.	$10.03 -0.4%	$10.11	$8.01 ▼ $23.10	$2.61B	0.58	3.41 million shs	3.33 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	+0.60%	+9.34%	+26.81%	-9.25%	-7.87%
BMY Bristol-Myers Squibb	+1.10%	+5.95%	+8.80%	-14.11%	+19.50%
GPH Graphite One	-1.25%	-15.05%	0.00%	-18.56%	+9.72%
OGN Organon & Co.	-0.35%	+9.69%	+19.45%	-34.34%	-51.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.7044 of 5 stars	3.6	1.0	0.0	0.0	3.8	3.3	0.0
BMY Bristol-Myers Squibb	4.8673 of 5 stars	3.2	5.0	4.2	4.0	3.4	3.3	0.0
GPH Graphite One	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	4.8032 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	242.68% Upside
BMY Bristol-Myers Squibb	2.32	Hold	$58.00	16.69% Upside
GPH Graphite One	0.00	N/A	N/A	N/A
OGN Organon & Co.	2.50	Moderate Buy	$18.00	79.55% Upside

Current Analyst Ratings Breakdown

Latest AURA, BMY, OGN, and GPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/5/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
4/25/2025	BMY Bristol-Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol-Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol-Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	BMY Bristol-Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol-Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$4.58 per share	N/A
BMY Bristol-Myers Squibb	$47.64B	2.12	$5.24 per share	9.48	$8.08 per share	6.15
GPH Graphite One	N/A	N/A	C$0.01 per share	94.17	C$0.44 per share	N/A
OGN Organon & Co.	$6.29B	0.41	$3.21 per share	3.12	($0.27) per share	-37.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$76.41M	-$1.90	N/A	N/A	N/A	N/A	-41.57%	-36.43%	8/8/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	$2.67	N/A	8.16	2.07	-18.53%	13.93%	2.46%	7/31/2025 (Estimated)
GPH Graphite One	-C$4.90M	-C$0.07	N/A	∞	N/A	N/A	-10.96%	-6.61%	N/A
OGN Organon & Co.	$864M	$2.88	3.01	2.68	0.90	13.49%	431.62%	8.03%	8/5/2025 (Estimated)

Latest AURA, BMY, OGN, and GPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion
4/24/2025	Q1 2025	BMY Bristol-Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
BMY Bristol-Myers Squibb	$2.48	4.99%	N/A	92.88%	17 Years
GPH Graphite One	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.80%	N/A	2.78%	N/A

Latest AURA, BMY, OGN, and GPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	12.47	12.47
BMY Bristol-Myers Squibb	2.90	1.25	1.15
GPH Graphite One	0.02	1.09	0.33
OGN Organon & Co.	17.73	1.70	1.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
BMY Bristol-Myers Squibb	76.41%
GPH Graphite One	0.07%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
BMY Bristol-Myers Squibb	0.09%
GPH Graphite One	28.81%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.25 million	Not Optionable
BMY Bristol-Myers Squibb	34,300	2.04 billion	2.03 billion	Optionable
GPH Graphite One	20	101.25 million	N/A	Not Optionable
OGN Organon & Co.	10,000	259.96 million	253.93 million	Not Optionable

AURA, BMY, OGN, and GPH Headlines

Recent News About These Companies

OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 13 at 4:00 PM | globenewswire.com

Levi & Korsinsky Notifies Organon & Co. (OGN) Shareholders of Class Action Lawsuit and July 22, 2025 Deadline

June 13 at 4:00 PM | accessnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OGN

June 13 at 4:00 PM | accessnewswire.com

OGN CLASS ACTION NOTICE: Organon & Co. was Sued for Securities Fraud; Contact BFA Law if You Suffered Losses

June 13 at 3:18 PM | accessnewswire.com

Lost Money on Organon & Co. (OGN)? Urged to Join Class Action Before July 22, 2025 - Contact Levi & Korsinsky

June 13 at 3:15 PM | accessnewswire.com

Lost Money on Organon & Co. (OGN)? Join Class Action Before July 22, 2025 - Contact Levi & Korsinsky

June 13 at 1:30 PM | accessnewswire.com

Class Action Filed Against Organon & Co. (OGN) - July 22, 2025 Deadline to Join – Contact Levi & Korsinsky

June 13 at 1:26 PM | globenewswire.com

Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

June 13 at 1:10 PM | globenewswire.com

Securities Lawsuit Alert: Organon & Co. (OGN) Investors - Contact Levi & Korsinsky Before July 22, 2025

June 13 at 12:45 PM | accessnewswire.com

Class Action Filed Against Organon & Co. (OGN) Over Securities Violations - Contact Levi & Korsinsky Today

June 13 at 11:15 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

June 13 at 11:00 AM | accessnewswire.com

Class Action Lawsuit Filed Against Organon & Co. (OGN) - Recover Losses - Contact Levi & Korsinsky Before July 22, 2025

June 13 at 10:45 AM | accessnewswire.com

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

June 13 at 10:13 AM | prnewswire.com

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

June 13 at 10:00 AM | zacks.com

Class Action Alert: Levi & Korsinsky Reminds Organon (OGN) Investors of July 22, 2025 Deadline

June 13 at 9:15 AM | accessnewswire.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm

June 13 at 9:00 AM | prnewswire.com

Shareholders of Organon & Co. (OGN): Protect Your Rights Before July 22, 2025 - Contact Levi & Korsinsky

June 13 at 8:05 AM | accessnewswire.com

Securities Fraud Class Action Filed Against Organon & Co. (OGN) - Levi & Korsinsky Reminds Investors of July 22, 2025

June 13 at 7:30 AM | accessnewswire.com

OGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Investors Have Opportunity to Lead Class Action Lawsuit!

June 13 at 7:00 AM | accessnewswire.com

Class Action Filed Against Organon & Co. (OGN) Seeking Recovery for Investors - Contact Levi & Korsinsky

June 13 at 5:45 AM | prnewswire.com

Wedmont Private Capital Sells 54,982 Shares of Organon & Co. (NYSE:OGN)

June 10 at 4:29 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Analysts Say Unilever Has the Leverage to Hit New Highs
By Thomas Hughes | May 15, 2025
View Analysts Say Unilever Has the Leverage to Hit New Highs

AURA, BMY, OGN, and GPH Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.42 -0.25 (-3.75%)

Closing price 04:00 PM Eastern

Extended Trading

$6.40 -0.02 (-0.30%)

As of 04:24 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Bristol-Myers Squibb NYSE:BMY

$49.70 -0.99 (-1.94%)

Closing price 03:59 PM Eastern

Extended Trading

$49.74 +0.04 (+0.08%)

As of 04:23 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Graphite One CVE:GPH

C$0.77 -0.02 (-2.53%)

As of 01:59 PM Eastern

Graphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Organon & Co. NYSE:OGN

$10.02 -0.05 (-0.45%)

Closing price 03:59 PM Eastern

Extended Trading

$10.00 -0.02 (-0.24%)

As of 04:11 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time